Country: Canada
Language: English
Source: Health Canada
MODAFINIL
TEVA CANADA LIMITED
N06BA07
MODAFINIL
100MG
TABLET
MODAFINIL 100MG
ORAL
30
Prescription
Wakefulness-Promoting Agents
Active ingredient group (AIG) number: 0136083001; AHFS:
APPROVED
2012-01-03
_ _ _Product Monograph _ _ _ _ALERTEC modafinil _ _Page 1 of 45 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR ALERTEC ®* modafinil Tablets, 100 mg, Oral Mfr. Std. Central Nervous System Stimulant Teva Canada Limited 30 Novopharm Court Toronto, Ontario Canada M1B 2K9 Marketed by: Teva Canada Innovation Montréal, Quebec H2Z 1S8 Date of Initial Authorization: February 26, 1999 Date of Revision: July 4, 2023 Submission Control Number: 272079 * ALERTEC is a registered trademark of Cephalon, Inc. Used under license by Teva Canada Innovation. _ _ _Product Monograph _ _ _ _ALERTEC modafinil _ _Page 2 of 45 _ RECENT MAJOR LABEL CHANGES 4 Dosage and Administration 11/2021 7 Warnings and Precautions, Alcohol Consumption, Risk of stroke 11/2021 7 Warnings and Precautions, Dependence/Tolerance 07/2023 9 Drug-Behavioural Interactions – Alcohol Consumption 07/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ...................................................................................... 2 TABLE OF CONTENTS ........................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ............................................................... 4 1 INDICATIONS ............................................................................................................... 4 1.1 Pediatrics ............................................................................................................. 4 1.2 Geriatrics ............................................................................................................. 5 2 CONTRAINDICATIONS ................................................................................................ 5 4 DOSAGE AND ADMINISTRATION .............................................................................. 5 4.1 Dosing Considerations ................................................................... Read the complete document